TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6344819
Drug: Pork mucosal
Normalized name: Pork
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork mucosal heparin
Study: 6344819
Drug: Both types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both types of heparin
Study: 31062842
Drug: Oral neuromuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neuromuscular training
Study: 22059736
Drug: Sitagliptin/metformin 50/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin/metformin 50/500 mg twice daily (up-titrated to 50/1000 mg twice daily)
Study: 22059736
Drug: Sitagliptin/metformin
Normalized name: sitagliptin/metformin HCl 50 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin/metformin
Study: 24738695
Drug: Canephron N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canephron N administered with standard antidiabetic therapy and ACE inhibitor
Study: 24738695
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy and ACE inhibitor alone
Study: 23744760
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (Arm A)
Study: 23744760
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy with sequential trastuzumab (Arm B)
Study: 23744760
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy with concurrent trastuzumab (Arm C)
Study: 18378744
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive users (77 women)
Study: 18378744
Drug: Non-oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-oral contraceptive users (200 women)
Study: 16181541
Drug: Xueshuantong and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xueshuantong and Betahistine Hydrochloride Injection (BHI), intravenous dripping, once daily for 14 days.
Study: 12907285
Drug: MCCh formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCCh formulations
Study: 24927607
Drug: Filibuvir 600
Normalized name: Filibuvir
DrugBank: Filibuvir (DB11878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filibuvir 600 mg BID plus pegIFN/ribavirin
Study: 17456679
Drug: Clonidine 0.0
Normalized name: clonidine 0.09 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.0 mug/mL (C0)
Study: 17456679
Drug: Clonidine 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 4.0 mug/mL (C4)
Study: 2667109
Drug: Ciprofloxacin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1.5 g/day for seven days
Study: 2667109
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg/day for seven days
Study: 367479
Drug: Electro-convulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-convulsive therapy (ECT) - six brief pulse unilateral shocks under conventional anaesthesia and muscle relaxation
Study: 30680611
Drug: Lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (10 mg) and Zeaxanthin (2 mg) supplement
Study: 26452308
Drug: Child Life
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Life Therapy (CLT)
Study: 16714645
Drug: Iodixanol at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol at a flow rate of 5 mL/sec
Study: 16714645
Drug: Iodixanol at
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol at a flow rate of 3 mL/sec
Study: 2880603
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 1 mg
Study: 2880603
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 4 mg
Study: 2880603
Drug: ICI 141,292
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 141,292 (1, 2, and 4 mg)
Study: 2880603
Drug: Atenolol 5
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 5 mg
Study: 28079793
Drug: Dental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatments under general anesthesia (GA)
Study: 28079793
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GA treatment)
Study: 28079793
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (before treatment)
Study: 23841267
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (after treatment)
Study: 15132723
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (0.5, 1.0, and 1.7 IU/m(2) per day)
Study: 15132723
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GH treatment
Study: 3137026
Drug: Flumazenil i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil i.v. (0.35 +/- 0.15 mg)
Study: 25604134
Drug: Erlotinib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 50 mg
Study: 25604134
Drug: Erlotinib 100
Normalized name: erlotinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 100 mg
Study: 27391356
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen (TPF-E followed by PA-E with XRT)
Study: 20146063
Drug: Standard-dose EMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose EMP (560 mg/day)
Study: 20146063
Drug: PPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV plus low-dose EMP (280 mg/day)
Study: 16634855
Drug: Targeted naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted naltrexone (50 mg/day)
Study: 16634855
Drug: Daily naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily naltrexone (50 mg/day)
Study: 14985695
Drug: Daily placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo
Study: 19248200
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg once daily for 8 weeks)
Study: 9882027
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (bismuth subcitrate 120 mg, tetracycline 500 mg, metronidazole 400 mg, all given four times daily) plus omeprazole (20 mg once daily for 8 weeks)
Study: 8014510
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole (2g)
Study: 1097035
Drug: L-histidine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-histidine 4 g/day
Study: 2499203
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg praziquantel
Study: 29855373
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg praziquantel
Study: 24071051
Drug: Fluoroscopy guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy guided caudal epidural steroid injection (CESI)
Study: 24071051
Drug: Oral non-steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral non-steroidal anti-inflammatory drugs (NSAIDs)
Study: 21881324
Drug: Sivelestat sodium
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sivelestat sodium hydrate (0.2 mg/kg/h until weaning from mechanical ventilation)
Study: 11272721
Drug: HEP A
Normalized name: Hep A, IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP A vaccine (25 units in 0.5 mL)
Study: 11272721
Drug: HEP A
Normalized name: Hep A, IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP A & B vaccines concurrently (HEP A: 25 units in 0.5 mL; HEP B: 10 micrograms in 1.0 mL)
Study: 11272721
Drug: HEP B
Normalized name: Bayhep B
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEP B vaccine (10 micrograms in 1.0 mL)
Study: 9517592
Drug: Inhaled NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled NO concentration of 20 ppb
Study: 9517592
Drug: Inhaled NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled NO concentrations of 49 ppb, 98 ppb, and 148 ppb
Study: 2488113
Drug: Propranolol (PPL)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (PPL) 180-240 mg
Study: 2488113
Drug: Pindolol (PDL)
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol (PDL) 15-45 mg
Study: 769949
Drug: Standard-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclophosphamide (3 mg/kg/day)
Study: 769949
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose cyclophosphamide (10 mg/kg/day for 4 days out of 14)
Study: 769949
Drug: Cyclophosphamide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (3 mg/kg/day) plus cytosine arabinoside (3 mg/kg/week im)
Study: 31764989
Drug: Sodium thiosulphate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulphate (NaTS) 25 g/1.73 m2
Study: 27827284
Drug: Extracorporeal shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shockwave therapy (ESWT)
Study: 21802630
Drug: Clonidine group
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine group (n = 40) received 4.5 mL of lidocaine‐bupivacaine and 0.5 μg/kg of clonidine in a 0.5 mL volume
Study: 16647884
Drug: Tiagabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine monotherapy
Study: 12297808
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg once daily for 10 days
Study: 8542742
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic patients without complications
Study: 8542742
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic patients with microvascular disease
Study: 21512411
Drug: EBTA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBTA group (Esomeprazole, Bismuth subcitrate, Tetracycline, Amoxicillin)
Study: 17130343
Drug: Probenecid 1000
Normalized name: probenecid 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid 1000 mg
Study: 31719005
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin C
Study: 15311720
Drug: EZE +
Normalized name: Acetaminophen 650 MG Oral Tablet [PAIN-EZE +/RHEU-THRITIS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE + ATV 10 mg
Study: 9067720
Drug: Sillix Donna
Normalized name: ATROPA BELLA-DONNA FLOWERING TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sillix Donna (active preparation)
Study: 2946313
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of fentanyl and alfentanil
Study: 31655134
Drug: Glecaprevir-pibrentasvir 300
Normalized name: glecaprevir / pibrentasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks with simplified monitoring
Study: 31655134
Drug: Standard monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monitoring with glecaprevir-pibrentasvir 300 mg-120 mg daily for 8 weeks
Study: 31556670
Drug: Motivational enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational enhancement therapy (MET) combined with cognitive-behavioral therapy (CBT)
Study: 24831251
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) alone
Study: 31556670
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; 12-step facilitation, supportive therapy)
Study: 28586233
Drug: DentalVibe® Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DentalVibe® Injection Comfort System (DV3)
Study: 23458449
Drug: Complete steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete steroids avoidance (n = 50)
Study: 23458449
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 50)
Study: 14628279
Drug: Hydroxyurea (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (500 mg bid) plus didanosine (400 mg qd)
Study: 1868748
Drug: Naftifine gel
Normalized name: naftifine Topical Gel
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine gel 1 percent
Study: 3048914
Drug: Naftifine cream
Normalized name: naftifine Topical Cream
DrugBank: Naftifine (DB00735)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naftifine cream 1 percent
Study: 2805810
Drug: Econazole nitrate
Normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Econazole nitrate cream 1 percent
Study: 2805810
Drug: Clotrimazole cream
Normalized name: Clotrimazole Cream
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole cream 1 percent
Study: 31515250
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon alfa-2a (PEG) therapy
Study: 22976131
Drug: 21/2 placebo/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21/2 placebo/5 ethinyl estradiol 10 μg regimen (group 2)
Study: 17346247
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill
Study: 10653925
Drug: Aggressive cholesterol-lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive cholesterol-lowering therapy with atorvastatin
Study: 1658953
Drug: Nonoxynol-9 (N-9),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 (N-9), 150 mg, used cumulatively four times a day for 14 days
Study: 31600598
Drug: XF-73 2.0mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: XF-73 2.0mg/g 2% gel
Study: 31226190
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant planning and freehand placement (control group, n = 26)
Study: 31226190
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant planning and freehand placement (control group)
Study: 25032713
Drug: Regular-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular-dose atorvastatin (10 mg)
Study: 22972399
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (80 mg)
Study: 24858750
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lycopene/day for 2 weeks with oral prophylaxis (full mouth scaling and root planing completed within 24 hours)
Study: 29217959
Drug: Oral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis only
Study: 21996647
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg intravenous infusion)
Study: 1647496
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg subcutaneous injection)
Study: 19243818
Drug: IL-12 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-12 300 ng/kg subcutaneously twice weekly for 24 weeks
Study: 19243818
Drug: IL-12 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks (initial treatment)
Study: 16521225
Drug: CIFN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIFN with polaprezinc 300 mg (regimen A, n=41)
Study: 3295620
Drug: Monthly myelosuppressive
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly myelosuppressive maintenance chemotherapy after TAD9-induction and consolidation
Study: 27406394
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg twice daily) plus metformin [500 mg twice daily] (VLDM group)
Study: 27406394
Drug: Metformin uptitration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin uptitration [1000 mg twice daily] (HDM group)
Study: 7837862
Drug: Standard ORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ORS (311 mmol/L)
Study: 31215874
Drug: 18% ethylenediaminetetraacetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18% ethylenediaminetetraacetic acid (EDTA) water solution
Study: 30019676
Drug: 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg iodine/day from a multivitamin supplement for pregnant and lactating women
Study: 23047502
Drug: Sodium ferulate
Normalized name: ferulate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferulate (SF) 150 mg three times daily for fourteen days
Study: 19941078
Drug: Intranasal mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal mometasone
Study: 2964995
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide and salbutamol therapy (combined)
Study: 2964995
Drug: Nebulized ipratropium
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized ipratropium bromide and salbutamol therapy (separately)
Study: 31017585
Drug: Weekly serial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly serial self-measurements of waist and hip circumference combined with motivational text messages for 8 weeks
Study: 23642330
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Anorexia Nervosa (CBT-AN)
Study: 20073139
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention to improve medication adherence
Study: 17196664
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (bifrontal and right unilateral ECT)
Study: 3061715
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid solution (dilute and hyperosmolar)
Study: 3061715
Drug: Hyperosmolar saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar saline solution
Study: 31953540
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Carbohydrate (VLC) diet (14%E carbohydrate, <50 g/d; 28%E protein; 58%E fat)
Study: 25925398
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral escalating immunotherapy
Study: 11762557
Drug: Ortho Evra
Normalized name: Ortho Evra
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ortho Evra contraceptive patch
Study: 8669219
Drug: Cimetidine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1200 mg) administered by infusion pump over 24 hrs
Study: 8669219
Drug: Ranitidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (200 mg) administered by infusion pump over 24 hrs
Study: 2677055
Drug: Oral flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flurbiprofen (100 mg/day) + toothbrushing (A)
Study: 2677055
Drug: Oral flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral flurbiprofen (100 mg/day) only (C)
Study: 699626
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg diflunisal twice daily
Study: 6544198
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ibuprofen 3-times daily
Study: 24998009
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections
Study: 25467848
Drug: PBT2 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBT2 100 mg
Study: 22808020
Drug: Oral rinse
Normalized name: Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse (60 seconds with chlorhexidine followed by 60 seconds with nystatin)
Study: 22808020
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral rinse
Study: 19165563
Drug: Levosimendan (L)
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (L)
Study: 15590210
Drug: HRT every
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT every day (0.625 mg CEE and 2.5 mg MPA)
Study: 12199798
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) for 5-7 days
Study: 12199798
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) reviparin for 5-7 days (short-treated group)
Study: 12199798
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) reviparin for 28 days (long-treated group)
Study: 1811606
Drug: Intravenous gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gamma immunoglobulin (IVIG)
Study: 30757935
Drug: Eclipta prostrata
Normalized name: ECLIPTA PROSTRATA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eclipta prostrata (EP) 1 mg/day
Study: 30757935
Drug: Eclipta prostrata
Normalized name: ECLIPTA PROSTRATA LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eclipta prostrata (EP) 10 mg/day
Study: 30757935
Drug: Topical 3%
Normalized name: sulfur topical 3% topical soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 3% minoxidil
Study: 30289329
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (CsA) treatment (4 times daily in both eyes for a month before HSCT and continued use after transplantation)